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Abstract
Adipose tissue is no longer considered to be solely an energy storage, but exerts important
endocrine functions, which are primarily mediated by a network of various soluble factors derived
from fat cells, called adipocytokines. In addition to their responsibility to influence energy
homeostasis, new studies have identified important pathways linking metabolism with the immune
system, and demonstrating a modulatory role of adipocytokines in immune function. Additionally,
epidemiological studies underline that obesity represents a significant risk factor for the
development of cancer, although the exact mechanism of this relationship remains to be
determined. Whereas a possible influence of adipocytokines on the proliferation of tumor cells is
already known, new evidence has come to light elucidating a modulatory role of this signaling
substances in the regulation of migration of leukocytes and tumor cells. The migration of leukocytes
is a key feature to fight cancer cells, whereas the locomotion of tumor cells is a prerequisite for
tumor formation and metastasis. We herein review the latest tumor biological findings on the role
of the most prominent adipocytokines leptin and adiponectin, which are secreted by fat cells, and
which are involved in leukocyte migration, tumor growth, invasion and metastasis. This review thus
accentuates the complex, interactive involvement of adipocytokines in the regulation of migration
of both leukocytes and tumor cells, and gives an insight in the underlying molecular mechanisms.
Introduction
The prevalence and incidence of obesity and obesity-
related diseases has increased dramatically over the past
decades. Globally, the overweight population has
exceeded one billion, and epidemiologic data collected
clearly demonstrate that obesity in adults is associated
with an increased risk of cardiovascular disease, diabetes,
and numerous other health disorders [1]. Traditionally,
fat tissue was considered to be solely an energy storage
depot having only a passive function in the body. How-
ever, recent studies have shown that fat tissue exerts
important endocrine functions, which are orchestrated by
a complex network of various soluble factors derived from
adipocytes (fat cells), called adipocytokines. These are a
group of novel and highly active molecules, which are
abundantly secreted by adipocytes, and act at both the
local and systemic level [2]. Since their discovery in the
early 90s, around 20 members of the adipocytokine fam-
ily have been identified so far [3]. Adiponectin and leptin
are the most abundant adipocytokines produced by adi-
pocytes, and the best-studied molecules in this class so far.
In addition to their responsibility to influence energy
homeostasis, new studies have identified important path-
ways linking metabolism with the immune system and
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vice versa. Obesity is associated with a state of chronic low
level inflammation, which is characterized by abnormal
cytokine production and the activation of pro-inflamma-
tory signaling pathways. Above all, new evidence eluci-
dates their modulatory role in regulating cancer
development [3,4]. Epidemiological studies further sup-
port an increased risk of cancer in obese individuals [5-7],
although the exact mechanisms and thus prospects for
therapeutic intervention are still unidentified.
Cell migration is an essential characteristic of both physi-
ological and pathological processes within the human
body. The migratory capacity of immune cells is a manda-
tory component for host immune surveillance, in which
e.g. leukocytes from the circulation migrate into the sur-
rounding tissues to destroy invading microorganisms and
infected cells, whereas the migration of tumor cells is a
prerequisite for tumor cell invasion and metastasis forma-
tion. Migratory activity is not an intrinsic function of the
cells, but a process that is regulated by extracellular signal
substances from other tissues and organ systems within
the body. We have repeatedly shown that external signal
substances such as neurotransmitters and cytokines signif-
icantly stimulate the migration of tumor cells and leuko-
cytes [8,9]. Although several effects of adipocytokines on
cells of the immune system and tumor cells have been
described before, it is not known how the migratory activ-
ity of these cells is affected and the participating molecules
and pathways are not yet identified. So, being aware of the
alarmingly number of obese patients worldwide, this
review aims to illuminate the latest findings on the role of
adipocytokines in leukocyte migration, tumor growth,
invasion and metastasis.
Understanding this rapidly growing family of adipocy-
tokines and their mode of action would represent a break-
through research in obesity and cancer, and will open new
avenues for future development of obesity- and cancer-
associated therapeutics.
Leptin - Effects on immune cells and tumor cells
A key molecule in obesity is leptin, a 16 kDa peptide hor-
mone predominantly produced by white adipose tissue
[10]. Circulating leptin is actively transported through the
blood-brain barrier and acts on the hypothalamic satiety
center to decrease food intake. The main function of lep-
tin in the human body is the regulation of energy expend-
iture and control of appetite. Indeed, lack of leptin in mice
with a mutation in the gene encoding leptin, or absence of
functional leptin receptor (db/db mice) results in obesity
and many associated metabolic complications such as
insulin resistance [11]. Serum level of leptin reflects the
amount of energy stored in the adipose tissue and is in
proportion to body fat mass [12], i.e. increased in obese
and decreased after several months of pronounced weight
loss [13].
Leptin acts via transmembrane receptors (OB-R), which
belong to the class I cytokine receptor family, such as the
receptors of interleukin-2 (IL-2), IL-3, IL-4, IL-6, IL-11, IL-
12, granulocyte colony-stimulating factor (G-CSF) or
leukemia inhibitory factor (LIF). The OB-R has at least six
isoforms, termed OB-R(a-f), which are generated prima-
rily by alternative splicing of the ob gene. They all share an
identical extracellular ligand-binding domain but differ in
their C-terminal regions [14]. Two main leptin receptor
isoforms dominate: the short leptin receptor isoform
(OB-Ra) and the long leptin receptor isoform (OB-Rb).
OB-Rb contains the full-length intracellular domain and
is believed to be the main leptin signaling receptor. OB-Rb
has full signaling capabilities and is able to activate the
JAK/STAT pathway, the major pathway used by leptin to
exert its effects [15]. High levels of this isoform exist in the
hypothalamus, but is represented on many other cell
types as well, such as adipocytes, osteoclasts, endothelial
cells, lung and kidney cells, mononuclear blood cells,
muscle, endometrial and liver cells [14]. OB-Ra and OB-
Rc are highly expressed in choroids plexus and microves-
sels, where they may play a role in leptin uptake or efflux
from the cerebrospinal fluid as well as in receptor medi-
ated transport of leptin across the blood-brain barrier
[16]; OB-Re, which lacks the intracellular domain, may
encode a soluble receptor. Consistent with leptin's role in
controlling appetite and energy metabolism, OB-Rs have
been found in the hypothalamus and adjacent brain
regions. However, the almost universal distribution of
OB-Ra and OB-Rb reflects the multiplicity of biological
effects in extraneural tissues, providing evidence for the
extreme functional pleiotropy of leptin [12].
Leptin plays important roles in both adaptive and innate
immunity, and humans lacking leptin function exhibit
impaired immunity. Accordingly, the leptin receptor is
found to be expressed on a variety of immune cells [17].
With regard to innate immunity, leptin is a direct potent
chemoattractant for monocytes and macrophages,
whereas the presence of full-length receptors on migrating
cells is required. In addition, leptin increases the recruit-
ment of blood monocytes via adipose-tissue derived
endothelial cells (EC) by stimulating the upregulation of
EC adhesion molecules necessary for the diapedesis of the
monocytes [18]. Acting on monocytes leptin induces the
release of other cytokines such as tumor necrosis factor
alpha (TNF-α) or interleukin-6 (IL-6) as well as CC-chem-
okine ligand 2 (CCL2) and vascular endothelial growth
factor (VEGF) [19]. Leptin is also able to stimulate the
chemokinesis of eosinophils [20], and the chemotaxis of
neutrophils [21,22]. However, whereas leptin alone
induces the migration of neutrophils and exerts by itself aCell Communication and Signaling 2009, 7:27 http://www.biosignaling.com/content/7/1/27
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chemoattractive effect comparable to that of well-known
formyl-methionyl-leucyl-phenylalanin [21], neutrophil
locomotion in response to classical chemoattractants is
inhibited by simultaneous treatment with leptin [22].
Most of these effects are mediated through the OB-Rb,
which is expressed mainly by endothelial cells and various
leukocytes. In adaptive immunity, leptin enhances T cell
proliferation and Th 1 proinflammatory cytokine produc-
tion in vitro, whereas nothing is known about the effect of
this adipocytokine on the migratory behaviour of T cells.
Acting on dendritic cells leptin activates them, licenses
them for Th 1 priming, and increases migratory perform-
ance [23].
Epidemiological studies have shown that obesity is a risk
factor for postmenopausal breast cancer, cancers of the
endometrium, colon and kidney, and malignant adeno-
mas of the oesophagus [3]. Obese individuals have
approximately a 1.5-3.5-fold increased risk of developing
these cancers compared with normal-weight individuals,
and it is estimated that 15 to 45% of these cancers are
attributable to overweight (BMI 25.0-29.9 kg/m2) and
obesity in Europe [24]. Moreover, in high income coun-
tries the attributable fraction of all cancers due to obesity
was estimated as 3% [25].
Functional leptin receptors are found to be expressed on
diverse cancer cells derived from different tissues such as
breast, colon or prostate [26-30]. The breast cancer cell
lines HTB-26 and ZR75-1 [27], the prostate cancer cell
lines DU145 and PC-3 [30], and various colon carcinoma
cell lines such as LS174T and HM7 [29] as well as SW480,
SW620 and HCT116 [26] all express OB-Ra and OB-Rb. In
breast cancer cell lines and in human primary breast car-
cinoma leptin receptor has been demonstrated to occur in
combination with leptin. Therein, leptin is able to induce
the growth of these cells via different pathways, can medi-
ate angiogenesis by inducing the expression of VEGF, and
promotes invasion and migration by transactivation of
the epidermal growth factor receptor (EGFR) [15]. A bidi-
rectional crosstalk between leptin and insulin-like growth
factor-I (IGF-I) signaling was also shown to stimulate
invasion and migration of breast cancer cells [31].
Thereby, IGF-I induced phosphorylation of Ob-Rb and
leptin induced phosphorylation of IGF-I receptor,
whereas cotreatment induced synergistic phosphorylation
and association of Ob-Rb and IGF-IR along with activa-
tion of downstream effectors, Akt and extracellular signal-
regulated kinase; in parallel this cotreatment synergisti-
cally transactivated EGFR. In 92% of breast carcinomas
examined leptin was found to be overexpressed, but in
none of the cases of normal breast epithelium. Remarka-
bly, distant metastasis was present in 34% of OB-R-posi-
tive tumors with leptin overexpression, but in none of the
cases where the tumors lacked OB-R expression or leptin
overexpression [32]. A multitude of other studies have
demonstrated that leptin mediates a significant increase
of proliferation in breast, colon, esophagal and prostate
cancer cells, too [3,27,30]. For example, Somasundar et al.
[30] showed that leptin induced in vitro proliferation and
inhibited apoptosis in DU145 and PC-3 prostate cancer
cell lines. In a murine model of preneoplastic Apc(Min/+)
colon epithelial cells leptin treatment was demonstrated
to promote cell proliferation by an autocrine IL-6 produc-
tion and trans-IL-6 signaling [33].
Moreover, leptin promotes the migration and invasion of
cells derived from glioma [34], chondrosarcoma [35],
colon carcinoma [29,36], hepatocellular and endometrial
carcinoma cells [37,38], as well as prostate cancer [28]. In
DU145 and PC-3 prostate cancer leptin significantly
enhanced cell migration and induced expression of VEGF,
transforming growth factor-beta1 (TGF-beta1), and basic
fibroblast growth factor (bFGF), and thus overall likely
contributes to the progression of prostate cancer [28].
Interestingly, Deo et al [39] observed differential effects of
leptin on the invasive potential of prostate carcinoma
cells depending on their androgen sensitivity. Androgen-
sensitive LNCaP cells showed a significant increase in cel-
lular proliferation upon treatment with leptin, whereas no
effect was observable on androgen-insensitive PC-3 and
DU145 cells. In contrast, leptin caused a significant dose-
dependent decrease in migration and invasion solely of
PC-3 and DU145 prostate carcinoma cell lines. These
results are further supported by our own experiments
demonstrating divergent effects of leptin on the prolifera-
tion and migration of carcinoma cells derived from differ-
ent tissues (Table 1). Whereas leptin enhanced the
proliferation of various breast carcinoma cell lines,
including MDA-MB-468 and MDA-MB-231, it did not
have any impact on the migratory activity of these cells.
However, in various human colon carcinoma cells leptin
significantly stimulated the locomotory behaviour of the
cells [26,29]. These contradictory leptin effects on the
migration and proliferation, especially of prostate and
breast carcinoma cells, might be ascribable to the hor-
mone-sensitivity of the cells. This conclusion is confirmed
by results which demonstrate an influence of leptin on
breast cancer development in relation to estrogen receptor
status [40], and illuminate the growth-inducing effect of
leptin in estrogen receptor-positive breast cancer cells by
its stimulation of aromatase expression and the accompa-
nied increase of estrogen levels through the aromatization
of androgens [15]. In summary, all these data clearly sup-
port a direct functional role of leptin in processes related
to cancer initiation and/or progression by promoting the
migration and proliferation of carcinoma cells, thus
resulting in metastatic development.
Leptin - Molecular mechanisms
Leptin acts through its receptor OB-R, which is a member
of the cytokine receptor family. Accordingly, leptin signal-Cell Communication and Signaling 2009, 7:27 http://www.biosignaling.com/content/7/1/27
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ing is thought to be transmitted predominantly by the
intracellular Janus kinase (JAK)-signal transducer and acti-
vator of transcription (STAT) pathway with the activation
of STAT-3 and extracellular signal-regulated kinase
(ERK)1/2 [3]. The engagement of OB-R by leptin leads to
JAK-2 phosphorylation, which can then recruit STAT-3
tyrosine phosphorylation, finally leading to a nuclear
translocation and stimulation of transcription. In addi-
tion, the leptin receptor is also known to intracellularly
activate MAPK pathway after leptin binding [41]. In
human endometrial and hepatocellular carcinoma cells
leptin was shown to promote proliferation and invasion
by rapidly stimulating the JAK/STAT-pathway and induc-
ing the phosphorylation of ERK and AKT, thus activating
these key signal transduction pathways associated with
cell growth and cell migration [37,38,42]. Recent studies
have shown that the ERK pathway is an attractive target for
anticancer therapies due to its central role in the regula-
tion of proliferation, invasiveness, and survival of tumors
[43]. AKT provides a survival signal protecting cells from
apoptosis induced by various stresses by multiple mecha-
nisms, such as the phosphorylation of Bad, glycogen syn-
thase-3, and caspase-9 [44]. The PI3K/AKT pathway is
frequently altered in human cancers, and an activation of
AKT is correlated e.g with invasive and metastasizing
breast tumors [45]. In leptin-treated human chondrosar-
coma, hepatocellular and endometrial carcinoma cells
AKT phosphorylation was found to be increased, and
inhibition of PI3K with specific inhibitors abolished lep-
tin-induced proliferation, migration and invasion
[35,37,38,42]. Other studies explain the leptin stimulat-
ing effect on migration and invasion of various carcinoma
cells through the increased expression of various matrix
metalloproteinase or integrins via an activation of the
nuclear factor κB (NFκB) pathway [34,35]. Moreover, in
colon carcinoma cells leptin-induced promotion of motil-
ity and invasion was mediated by an activation of PI3K
and src kinase pathways resulting in a stimulation of the
Rho GTPases rac1, cdc42 and rhoA, proteins known to
regulate cell migration by affecting the reorganization of
the actin cytoskeleton [29].
Adiponectin -Effects on immune cells and tumor cells
Adiponectin is a 30 kDa protein secreted exclusively by
white adipocytes. Adiponectin circulates as several mul-
timeric species, including a high molecular weight form
thought to be the most clinically relevant. Serum levels of
adiponectin are markedly decreased in individuals with
Table 1: Summary of the effects of leptin and adiponectin on migration and proliferation of various cancer cell lines
Breast Carcinoma Cells Colon Carcinoma Cells
MCF-7 MDA-MB-468 MDA-MB-231 SW480
Receptor expression
ObRI ++ + +
AdipoR1 ++ + +
AdipoR2 ++ + +
Migration
Leptin no no no +
Adiponectin no no no +
Leptin+Adipo.n o n o n o -
Proliferation
Leptin +19% +10% +44% +52%
Adiponectin +25% +18% +46% -31%
Leptin+Adipo. +16% +5% +61% +11%
Receptor expression was determined using flow cytometry, migratory activity was investigated using our three-dimensional cell migration assay, and 
cell proliferation after 96 hours was evaluated using well-established XTT assay. All methods were performed as described previously [9].Cell Communication and Signaling 2009, 7:27 http://www.biosignaling.com/content/7/1/27
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visceral obesity and states of insulin resistance, such as
type 2 diabetes mellitus and artherosclerosis. In contrast
to leptin, adiponectin seems to have several beneficial and
protective effects. Although its role has not been definitely
established, adiponectin was shown to have anti-inflam-
matory, vasculoprotective, and anti-diabetic effects. Adi-
ponectin is highly abundant in the circulation, with
plasma concentrations in healthy humans around 3-30
μg/ml [46], and has a broad spectrum of biological activ-
ities. Adiponectin increases the body's sensitivity to insu-
lin including stimulation of glucose uptake in skeletal
muscle and suppression of glucose production in liver,
and affects the lipid metabolism by decreasing tissue fatty
acid content and serum lipids. Interestingly, levels of adi-
ponectin in obese individuals have shown to be decreased
even though it comes primarily from adipose tissue. Adi-
ponectin acts through its two receptors, AdipoR1 and
AdipoR2, which have unique distributions and affinities
for the different forms of circulating adiponectin.
AdipoR1 is expressed widely in various tissues, including
breast tissue, with the highest level of expression in skele-
tal muscle, while AdipoR2 is most abundantly expressed
in the liver [46].
With regard to the immune system, Pang et al. [47] inves-
tigated that AdipoR1 is present approximately on 1% of T
cells, 93% of monocytes, 47% of B cells, and 21% of NK
cells, and the distribution of AdipoR2 was found to be
similar. Acting on adaptive immunity, adiponectin inhib-
its T cell activation and proliferation, although data
regarding adiponectin effects on adaptive immune
response are relatively spare. In adiponectin-deficient
mice, absence of adiponectin was associated with a 2-fold
increase in leukocyte-rolling and a 5-fold increase in leu-
kocyte adhesion in the microcirculation [48]. Here, we
show for the first time that adiponectin induced the
migratory activity of human neutrophil granulocytes
within a three-dimensional collagen matrix (from 13%
locomoting cells in the control to 39% locomoting cells
after stimulation with 1 μg/ml adiponectin; Fig. 1A),
whereas it did not have any effect on the migratory activity
of human CD8 T lymphocytes. This contradictory results
of adiponectin on neutrophil granulocytes could be a con-
sequence of the experimental setup. Whereas in the adi-
ponectin-deficient mice the behaviour of leukocytes
during the extravasation process was examined, we inves-
tigated in our study the migration of neutrophils, a proc-
ess subsequently following extravasation. This is of major
importance for the interpretation of the results, because
participating molecules and molecular mechanisms are
different in this course of action. Whereas the extravasa-
tion of neutrophils is primarily regulated by the interac-
tion of leukocytes with the endothelium via various
adhesion molecules such as selectins or N-cadherin [49],
the migratory process is mediated e.g. by the interaction of
the cells with the surrounding extracellular matrix via
integrins or stimuli-induced rearrangement of the
cytoskeleton [50]. In addition, adiponectin inhibits NF-
κB activation in endothelial cells and interferes with the
function of macrophages; treatment of cultured macro-
phages with adiponectin markedly inhibit their phagocy-
totic activity and their production of TNFα in response to
lipopolysaccharide stimulation [51]. It suppresses IL-2
enhanced cytotoxic activity of natural killer (NK) cells
without affecting basal NK cell cytotoxicity [52]. The exact
roles of adiponectin in inflammation and immunity, and
especially the underlying molecular mechanism, remain
to be defined.
Effect of adiponectin on the migration of human immune cells Figure 1
Effect of adiponectin on the migration of human 
immune cells. The adipocytokine adiponectin induced the 
migratory activity of human neutrophil granulocytes, but did 
not have any effect on the locomotion of CD8 T lym-
phocytes. We mixed 2.5 × 105 neutrophils or T cells with 
150 μl of a buffered collagen solution (pH 7.4; 1.67 mg/ml 
collagen type I) in the presence of 1 μg/ml adiponectin. The 
buffered collagen suspension was filled into self-constructed 
chambers and allowed to polymerize for 20 min at 37°C in a 
5% CO2 humidified atmosphere [9]. We recorded the loco-
motor activity of the cells by time-lapse videomicroscopy and 
subsequently analyzed the migratory behaviour by computer-
assisted cell tracking. The figure shows mean values of three 
independent experiments (90 cells were analyzed).
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Low serum levels of adiponectin are associated with sev-
eral metabolic diseases, including obesity and insulin
resistance in type-2 diabetes [53]. Moreover, evidence
from several studies indicates that serum levels of adi-
ponectin in vivo are inversely associated with the risk for
multiple cancers, including colon in men [54], prostate
[55] as well as breast and endometrium [56,57]. For
example, women with a high body mass index and low
plasma adiponectin have a risk of endometrial cancer that
is 6.5-fold that in women with normal body mass index
and higher adiponectin concentrations [58]. Interestingly,
the inverse association of adiponectin with breast cancer
risk was found solely among postmenopausal women,
and not among premenopausal women [56]. In postmen-
opausal women obesity has been shown to increase rates
of breast cancer consistently by 30-50% [59]. Recently,
elevated serum adiponectin levels were demonstrated to
be independently associated with childhood non-hodg-
kin's lymphoma (NHL) and poor prognosis. Moreover
NHL specimens expressed the adiponectin receptors, sug-
gesting that adiponectin may represent not only a poten-
tial clinically significant diagnostic and prognostic marker
but also a molecule that may be implicated in NHL patho-
genesis [60]. Adiponectin receptors are primarily found to
be expressed solely in the malignant and not in the nor-
mal control tissue, and the expression can differ by disease
stage. For example, in cancerous lung tissue expression of
adiponectin receptors was apparent only in the cancerous
lung tissue (64.2% AdipoR1 and 61.9% AdipoR2 in can-
cerous vs. 0% among noncancerous tissue). Specifically,
AdipoR1 was expressed in all disease types, but no differ-
ence was noted with disease stage, whereas AdipoR2 was
mainly expressed in the non-small cell carcinomas and
more prominently in the advanced disease stage (80%)
[61]. Thus obese individuals with low levels of adiponec-
tin could be at higher risk of developing tumors.
Adiponectin may influence cancer risk through its well
recognized effects on insulin resistance, but it is also plau-
sible that it acts on tumor cells directly, because several
tumor cell lines express AdipoR1 and AdipoR2. Hence,
adiponectin receptors are found to be expressed on breast
([62,63], Table 1), colon [64], and prostate [55] carci-
noma cells. Furthermore, adiponectin has been shown to
suppress tumor growth in mice, most likely due to inhibi-
tion of neovascularization through suppression of
endothelial cell proliferation, migration and survival [65].
Several recent studies found that adiponectin decreased
cell growth in various breast cancer cell lines such as MCF-
7, MDA-MB-231, SK-BR-3 [62,63], inhibited proliferation
in prostate cancer cell lines [66], and SW480 colon carci-
noma cells (Table 1). In contrast with findings in breast
and prostate cancer cell lines, adiponectin stimulated
colonic epithelial cell proliferation [67]. This is in accord-
ance with the results in our study, where we observed an
enhanced proliferation of various breast carcinoma cell
lines, including MDA-MB-468 and MDA-MB-231 upon
treatment with adiponectin (Table 1). Also, study of the
effects of adiponectin on the apoptosis of cancer cells in
vitro, which may well differ from the in vivo condition,
remains inconclusive. In some studies [68,69] apoptosis
was increased upon incubation with adiponectin, but this
was not observed in other studies [62,66]. These divergent
results might be caused by variations in experimental con-
ditions, because especially in vitro proliferation studies
have limitations; one is the fact that all these studies were
performed under serum-free conditions, which may favor
an inhibition of cell growth, whereas e.g. in our prolifera-
tion assay cells were grown with serum.
To date only two studies have investigated the physiolog-
ical relevance of the above data by examining the effects
of in vivo adiponectin administration on tumor growth
[65,68]. Animal studies showed that adiponectin supple-
ment therapy could inhibit the development of breast
tumors in nude mice, and mice treated with adiponectin
displayed a much lower degree of breast tumor metastasis
[68]. Although it was not possible to discriminate whether
the decreased metastasis was caused by the direct suppres-
sive effects of adiponectin on cell migration and invasion
or is simply secondary to the reduced sizes of primary
tumors [68], these data clearly support a role of adiponec-
tin in breast cancer progression.
With regard to cell migration we observed differences for
the impact of adiponectin on the migratory behaviour of
tumor cells. Herein, we show for the first time that adi-
ponectin significantly stimulated the migration of human
SW480 colon carcinoma cells, whereas it did not have any
effect on the locomotion of various breast carcinoma cells
(Table 1). In accordance with the pro-migratory effect on
colon carcinoma cells demonstrated herein, very recently
two studies report that adiponectin increased the motility
of human prostate cancer cells [70] and chondrosarcoma
cells [71], too. Although adiponectin research with regard
to metastasis is at the beginning, current results on its
effects on the migratory and proliferative activity of carci-
noma cells indicate a distinct role of this adipocytokine in
cancer pathogenesis.
Adiponectin
Signaling pathways linking adiponectin with carcinogenesis
Despite the mounting experimental data, the molecular
mechanisms through which adiponectin mediates its
effects have not been fully elucidated. Possible mecha-
nisms, especially for its antiproliferative effects, have been
reviewed in detail by Kelesidis et al. [46]. Adiponectin, via
its specific receptors, mediates several signaling pathways
such as 5'-AMP-activated protein kinase (AMPK), peroxi-
some-proliferators-activated receptor (PPAR)-α and p38Cell Communication and Signaling 2009, 7:27 http://www.biosignaling.com/content/7/1/27
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mitogen-activated protein (MAP) kinase. Several studies
strongly suggest that both the antiproliferative and pro-
apoptotic effects of adiponectin are mediated by AMPK
[69,72]. Activation of AMPK inhibits enzymes that regu-
late protein, fatty acid, and triglyceride synthesis, includ-
ing mammalian target of rapamycin (mTOR), fatty acid
synthase, and glycerol phosphate acyltransferase [73]. In
addition, activated AMPK positively regulates two impor-
tant proteins for the control of growth arrest and apopto-
sis, p53 and p21 [73]. In MCF-7 breast carcinoma cells,
adiponectin-mediated antiproliferative responses were
also accompanied by an inhibition of MAP kinase path-
way [69], which is known to be associated with a decrease
of cell proliferation e.g. in human osteoblasts. More
recently, c-Jun NH2-terminal kinase (JNK) and STAT-3
were also shown to be downstream effectors of adiponec-
tin [74]. It has been demonstrated that adiponectin stim-
ulates JNK activation, which is involved in the regulation
of cell proliferation and apoptosis during various physio-
logical and pathological events, such as tumor develop-
ment [75]. STAT-3 also regulates cellular functions such as
cell proliferation, survival, differentiation as well as apop-
tosis, and dysregulation of the STAT system directly con-
tributes to malignant transformation and cancer
progression [76]. Adiponectin was shown to stimulate
JNK activation in prostate cancer DU145, PC-3, and
LNCaP-FGC cells, hepatocellular carcinoma HepG2 cells,
and C2C12 myoblasts, but also drastically suppress con-
stitutive STAT-3 activation in DU145 and HepG2 cells
[74]. This suggests that JNK and STAT-3 may constitute a
universal signaling pathway to mediate adiponectin's
pathophysiological effects on metabolic syndrome and
the pathogenesis of cancer. Very recently, adiponectin was
identified to reduce mRNA levels of genes involved in cell
cycle regulation (MAPK-3, ATM) and apoptosis (BAG-1,
BAG-3, MX-1, TP53) [77].
With regard to the molecular mechanisms mediating the
pro-migratory effects of adiponectin the investigations
have just started. Very recently, adiponectin was shown to
increase the motility of human prostate cancer [70] and
chondrosarcoma cells [71] via a transcriptional upregula-
tion of integrins and activations of p38, AMPK, and NFκB-
cascades. In endothelial progenitor cells adiponectin pro-
moted the migration activities mainly through the phos-
phorylation of AKT and the activations of Cdc42 and Rac1
[78]. In summary, although an increasing number of stud-
ies confirm and improve the existing findings, there is
more to be studied to better understand the mechanisms
underlying the antiproliferative as well as the pro-migra-
tory effects of adiponectin.
Conclusions
The cause of cancer has seemingly been pinned down to
be due to fundamental aberrations of cellular functions,
which also include many aspects of molecular biology.
The pathway of tumor formation is a multistep journey
including at least six essential alterations in cell physiol-
ogy that collectively dictate malignant growth and the
spread of transformed cell clones [79]. Besides these alter-
ations which have a genetic basis, tumor tissue is not to be
regarded as an independent entity isolated and set apart
from the body's environment, but is highly dependent
upon a multitude of factors that have been suggested to
promote and impair cancer progression. A prerequisite for
tumor cell invasion and metastasis formation is the capa-
bility of malignant cells for active migration. This cellular
process is regulated by a myriad of external signals such as
chemokines and neurotransmitters [8].
Obesity is related to a condition of chronic inflammation
characterised by abnormal production of inflammatory
cytokines with local effects e.g. TNFα or systemic effects
e.g. IL-6, that can contribute to the pathogenesis of malig-
nant diseases. Chronic inflammation induced by obesity
can affect both tumor initiation and tumor progression,
such as adipocyte-conditioned medium can e.g. promote
tumor migration [36]. Balkwill and Mantovani's study
elaborated on Virchow's theory of a connection between
inflammation and cancer [80], in which they describe the
attraction of leukocytes toward tumor cells, initiated
through tumor-released chemokines; they likewise postu-
lated the attraction of tumor cells by other chemokine-
producing cells. In recent years, improved understanding
of the inflammatory microenvironment of malignant tis-
sues has supported this hypothesis. Furthermore, previous
studies of our group have extended a functional interplay
between cancer progression and its environment, demon-
strating a strong impact of the nervous system on the
migration of leukocytes and tumor cells, too [8]. Apart
from the effect they inherently have on leukocytes causing
activation as well as migration of these cells, they also
mediate the neo-angiogenesis of malignant tissue, and
regulate directed metastatic migration. The effects of adi-
pocytokines on the migration of tumor cells, which are
herein reviewed, give further credence to Balkwill and
Mantovani's hypothesis. Accordingly, as summarized in
Table 2, leptin and adiponectin are shown to participate
in the process of carcinogenesis, including the migration
of tumor cells, and in the immune response. Leptin and
adiponectin, the most abundant adipocytokines pro-
duced by adipocytes and the best studied members of this
family, stimulate growth, migration and invasion of can-
cer cells in vitro, thus displaying a capacity for promoting
malignant biological behavior of cancer. Interestingly,
leptin and adiponectin show in vivo strongly varying
serum concentrations. Leptin concentrations in vivo are
high in obese patients, whereas adiponectin levels in the
blood decrease with body mass index and leptin increases.
Consequently, investigating the effectiveness of these adi-Cell Communication and Signaling 2009, 7:27 http://www.biosignaling.com/content/7/1/27
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pocytokines alone delivers different results on tumor cells
than in presence of more than one adipocytokine. For
example, adiponectin was shown to inhibit leptin-
induced cell proliferation in preneoplastic colon epithe-
lial cells by inhibiting leptin-induced NFκB-dependent
autocrine IL-6 production and trans-IL-6 signaling. Thus
adiponectin may be an important regulator of colon epi-
thelial cell homeostasis by linking the observed reduced
risk for cancer in populations with high serum adiponec-
tin concentrations to specific mechanism of cell number
homeostasis [81]. Recently, we could demonstrate in our
own studies, that adiponectin and leptin alone signifi-
cantly stimulated the migration of SW480 colon carci-
noma cells, respectively, whereas the combination of both
negated these pro-migratory effects (data not shown).
Taken together, these results suggest that the balance in
the concentrations of adipocytokines such as leptin and
adiponectin ultimately determines the consequences of
these substances for the immune response and the tumor
progression. However, the exact molecular mechanisms
of these adipocytokines are still unsolved, and it is
unlikely that there is a "one system fits all" mechanism
for. Thus, further studies illuminating the signaling path-
ways of the single adipocytokines, but also possible cross-
regulations with intracellular cascades activated by other
more recently discovered adipocytokines, hormones,
cytokines or growth factors, will be needed.
In summary, this review clarifies the enormous wide range
of efficacy adipocytokines such as leptin and adiponectin
do have in vivo on leukocytes and tumor cells besides their
already known physiological functions. The pathophysio-
logical and biological mechanisms underpinning these
associations are only starting to be understood. There is a
necessity to further investigate and characterize their
modes of action that link obesity and inflammation as
well as cancer for future design of novel therapeutics for
the treatment but also prevention of obesity-associated
carcinoma without hindering the immune response.
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Table 2: Summary of the general and specific function of adipocytokines
Molecule Function/effect in general Leukocyte function References Function and cancer type References
Leptin Satiety and appetite; signals to 
the brain to regulate energy 
homoeostasis and body weight.
Chemoattractant of 
neutrophils, monocytes & 
macrophages; stimulates 
chemokinesis of eosinophils
[18,20-22] Promotes migration & invasion 
of chondrosarcoma, glioma, 
colon, endometrial prostate & 
hepatocellular carcinoma cells
[28,29,34-38]
Adiponectin Regulator of energy 
homoeostasis: enhances insulin 
sensitivity and glucose uptake; 
has anti-inflammatory 
properties.
Stimulates the migration of 
neutrophils & inhibits 
phagocytotic activity of 
macrophages.
[51]
Figure 1
Suppresses growth in breast, 
colon & prostate cancer cell 
lines
Stimulates the migration of 
chondrosarcoma, colon & 
prostate carcinoma cells
[62,63,67,70,71]
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